Published: 2018-04-25

Association between components of metabolic syndrome with chronic kidney disease in Benin City, Nigeria

Oghenekaro G. Egbi, Evelyn I. Unuigbe, Efosa Oviasu


Background: The metabolic syndrome (MetS) is a constellation of risk factors of metabolic origin that promote the development of cardiovascular disease. More recently, an association with chronic kidney disease (CKD) is being reported. However, most of these studies are non-indigenous. The aim of the study was to determine the association between components of MetS and CKD in a Nigerian population.

Methods: Patients with MetS were recruited from a tertiary hospital in Benin City, Nigeria. Blood pressures and body mass indices were measured. Plasma glucose, serum lipids, urea and creatinine and spot urine albumin: creatinine ratio were analyzed. CKD was defined as estimated glomerular filtration rate <60mls/min+ urinary ACR >30mg/g creatinine.

Results: Obesity, waist/hip ratio, diastolic blood pressure, total cholesterol and LDL-cholesterol were associated with CKD in univariate analysis. Body mass index and diastolic blood pressure were independent predictors of CKD. There was a relationship between the number of MetS traits and CKD.

Conclusions: CKD in patients with MetS may therefore result from a synergistic effect of components of the syndrome. Diastolic blood pressure and obesity may predict CKD in MetS patients. Early detection and treatment of obesity and hypertension may thus be a strategy to target the increasing prevalence of renal disease in MetS.


Chronic kidney disease, Metabolic syndrome, Nigeria, Obesity

Full Text:



Locatelli F, Pozzoni P, Vecchio LD. Renal manifestations in the metabolic syndrome. Proceedings of the Fourth Genoa Meeting on Hypertension, Diabetes, and Renal Diseases. J Am Soc Nephrol. 2006;17:81-5.

International Diabetes Federation. Information on the IDF consensus worldwide definition of the metabolic syndrome. Available at: http://www.idf. org/webdata/docs/IDF_Meta_def_final.pdf. Accessed 2015 June 4.

Oguoma VM, Nwose EU, Richards RS. Prevalence of cardio-metabolic syndrome in Nigeria: systematic review. Public Health. 2015;129(5):413-23.

Nitta K. Possible link between metabolic syndrome and chronic kidney disease in the development of cardiovascular disease. Cardiology Research and Practice. 2011;2011.

Korantzopoulos K, Elisaf M, Millionis HJ. Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney disease-ready for prime time? Nephrol Dial Transplant. 2007;22(10):2768-74.

Zimmet P, Albati G, Shaw J. Worldwide definition of the metabolic syndrome: the rationale and the results. Diabetes Voice. 2005;50(3):31-3.

Araoye MA. Subject selection in research methodology with statistics for health and social sciences. 1st Ed. LLORIN. Nethedex. 2003;6:115-21.

Ulasi II, Ijoma CK, Onodugo OD. A community-based study of hypertension and cardiometabolic syndrome in semi-urban and rural communities in Nigeria. BMC Health Serv Res. 2010;10:71.

Kessler RC, Ronald C. National Comorbidity Survey, 1990-1992. Ann Arbor, Mich: Inter-University Consortium for Political and Social Research. 2000.

Chobain AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the Joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560-72.

Snijder MB, Van Dam RM, Visser M, Seidell JC. What aspects of body fat are particularly hazardous and how do we measure them? Int J Epidemiol. 2006;35:83.

Helger R, Rinfrey H, Hilgenfeldt. Direct estimation of creatinine in serum and urine without deproteinization using a modified Jaffe’s method. Z Klin Chem Klin Biochem. 1974;12(7):344-9.

Fawcett JK, Scott JE. Estimation of urea by Urease- Berthelot colorimetric method. J Clin Path. 1960;13:156.

Lothar T. Cholesterol enzymatic endpoint method in Clinical Laboratory Diagnostics. Frankfurt/main. Germany: TH books Verlagsgesellschaft mbH. 1st Edi. 1998.

Lopes-Virella MF. Determination of high density lipoprotein cholesterol by precipitant method. Clinical Chemistry. 1972;18:49.

Tieyz NW. Assay of triglycerides glycerol phosphate oxidase-PAP method in Clinical guide to laboratory tests. Second edit. Philadelphia (USA): WB Saunders: 1990;554-6.

Friedwald WT. Formula for calculation of low density lipoprotein cholesterol. Clin Chem. 1972;18:499.

Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation and treatment of high blood cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002;106:31-43.

Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.

Levey AS, Bosch JP, Lewis JP. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Diseases Study Group. Ann Intern Med. 1999;130:461-70.

Kalk WJ, Joffe BI. The metabolic syndrome, insulin resistance and its surrogates in African and white subjects with type 2 diabetes in South Africa. Metab Syndr Relat Disord. 2008;6(4):247-55.

Tanaka H, Shiohira Y, Higa A, Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006;69:369-74.

Hsu C, McCulloch CE, Iribaren C, Darbinlan J, Allan S. Body mass index and risk for End-stage Renal Disease. Ann Intern Med. 2006;144:21-8.

Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new onset kidney disease in a community based population. JAMA. 2004;291:844-50.

Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003;14:479-87.

Iseki K, Isemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870-6.

Noori N, Hosseinpanah F, Nasiri AA, Azizi F. Comparison of overall obesity and abdominal adiposity in predicting chronic kidney disease incidence among adults. J Ren Nutr. 2009;19(3):228-37.

Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among non diabetic adults. J Am Soc Nephrol. 2005;16:2134-40.

Chen J, Gu D, Chen CS, Wu X, Hamm LL, Muntner P, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007;22(4):1100-6.

Lea J, Cheek D, Thornley-Brown D. Metabolic Syndrome, proteinuria `and the risk of progressive CKD in hypertensive, African Americans. Am J Kidney Dis. 2008;51(5):732-40.

Akinsola W, Odesanmi WO, Ogunniyi JO, Ladipo GO. Diseases causing chronic renal failure in Nigerians-a prospective study of 100 cases. Afr J Med Med Sci. 1989;18(2):131-7.

Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA. 1997;277(16):1293-8.

Schaeffner ES, Kurth T, Bowman TS, Gelber RP, Gaziano M. Blood pressure measures and risk of chronic kidney disease in men. Nephrol Dial Transplant. 2007;23(4):1246-51.

Izzo UB, Levey D, Black HR. University At Buffalo. Systolic-Not Diastolic-Blood pressure Reading should define Hypertension, New NIH Clinical Advisory States. Science Daily. 2000.

Franklin SS, Gustin W, Wong ND. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96:308.

Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, Diabetes, and cardiovascular risk in non- diabetic adults. N Engl J. 2010;362:800-11.

Moorehead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet. 1982;11:1309-11.

Schaeffner ES, Kurth T, Curhan GC. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084-91.

Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag JM. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293-301.

Colhoun HM, Lee ET, Bennett PH. Risk factors for renal failure: The WHO multinational study of vascular disease in diabetes. Diabetol. 2001;44(Suppl 2):S46-S53.